Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

Kastritis, Efstathios; Palladini, Giovanni; C. Minnema, Monique; Wechalekar, Ashutosh; Jaccard, Arnaud; C. Lee, Hans; Sanchorawala, Vaishali; Gibbs, Simon; Mollee, Peter; P. Venner, Christopher; Lu, Jin; Schönland, Stefan; E. Gatt, Moshe; Suzuki, Kenshi; Kım, Kihyun; Teresa Cibeira, M.; Beksaç, Meral; N. Libby, Edward; Valent, Jason; Hungria, Vânia; W. Wong, Sandy; Rosenzweig, Michael; Bumma, Naresh; Huart, Antoine; Α. Dimopoulos, Meletios; Bhutani, Divaya; Waxman, Adam; Goodman, Stacey; A. Zonder, Jeffrey; Lam, Selay; Song, Kevin; Hansen, Timon; Manier, Salomon; Roeloffzen, Wilfried; Jamroziak, Krzysztof; Kwok, Fiona; Shimazaki, Chihiro; Seok Kim, Jin; Crusoé, Edvan; Ahmadi, Tahamtan; Tran, NamPhuong; Qin, Xiang; Y. Vasey, Sandra; Tromp, Brenda; M. Schecter, Jordan; M. Weiss, Brendan; Hong Zhuang, Sen; Vermeulen, Jessica; Merlini, Giampaolo; L. Comenzo, Raymond

doi:10.1056/nejmoa2028631

Public

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

Published in New England Journal of Medicine • Jun 30, 2021

Authors:

Efstathios Kastritis

Giovanni Palladini

Monique C. Minnema

Abstract

BACKGROUND: Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease. METHODS: We randomly assigned patients with n...

Subject

Daratumumab

Medicine

AL amyloidosis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!